Neumora Therapeutics, Inc. Common Stock
Symbol: NMRA (NASDAQ)
1.64
▼ (-2.10%) -0.035
Company Description:
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Key Stats
- Today's Open: $1.68
- Today's High: $1.705
- Today's Low: $1.63
- Today's Volume: 228.54K
- Yesterday Close: $1.67
- Yesterday High: $1.68
- Yesterday Low: $1.62
- Yesterday Volume: 319.05K
- Last Min Volume: 8
- Last Min High: $1.635
- Last Min Low: $1.635
- Last Min VWAP: $1.635
Company Profile
- Name: Neumora Therapeutics, Inc. Common Stock
- Website: https://www.neumoratx.com
- Listed Date: 2023-09-15
- Location: WATERTOWN, MA
- Market Status: Active
- CIK Number: 0001885522
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $268.83M
- Round Lot: 100
- Outstanding Shares: 161.95M
- Asset Type: CS
RECENT FILINGS FOR NMRA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-11 | SCHEDULE 13G | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 8-K | View |
| 2025-05-23 | 4 | View |
| 2025-05-16 | DEFA14A | View |
| 2025-05-16 | 8-K | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
Latest News on NMRA